News Search Results
May 05, 2026, 06:17 ET Functional Membrane Separators Market to Reach $16183.29 billion, Globally, by 2035 at 8.1% CAGR: Allied Market Research
industrial separation processes. They are widely used across water purification facilities, energy systems, chemical processing plants, healthcare & biotechnology laboratories, and food & beverage processing industries, forming an essential component of modern separation infrastructure. With rise in concerns
More news about: Allied Market Research
May 05, 2026, 06:00 ET IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
preliminary or interim results; the ability to successfully develop, manufacture, and commercialize product candidates; competition from other biotechnology and pharmaceutical companies; the impact of global economic conditions; IDEAYA's ability to successfully establish, protect and defend its intellectual
More news about: IDEAYA Biosciences, Inc.
May 05, 2026, 05:00 ET Polyglycerol Fatty Acid Ester Market worth $310.9 million by 2031- Exclusive Report by MarketsandMarkets™
(France), Stéarinerie Dubois (France), Oleon NV (Belgium), Ataman Kimya A.Ş. (Turkey), Foodchem International Corporation (China), Guangzhou Cardlo Biotechnology Co., Ltd. (China), and Henan Chemsino Industry Co., Ltd. (China).Get 10% Free Customization on this Report:
More news about: MarketsandMarkets
May 05, 2026, 03:30 ET Strategic Partnerships in Focus: Gedeon Richter at Chessparty Stockholm
2.3bn in 2025, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing
More news about: Gedeon Richter Plc.
May 05, 2026, 00:30 ET HKU holds Entrance Scholarships Award Ceremony for 2025-26
student, highlighted her mother's resilience in battling a rare autoimmune disease as the inspiration behind her pursuit of Molecular Biology and Biotechnology at HKU. Despite financial constraints, her parents' unwavering support for her education encouraged Naziba to remain ambitious and hopeful. As a
More news about: The University of Hong Kong (HKU)
May 04, 2026, 17:04 ET Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD)
HOUSTON, May 4, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical stage biotechnology company, pioneering allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced that the U.S. Food and Drug Administration (FDA)
More news about: Cellenkos, Inc.
May 04, 2026, 16:40 ET Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD)
HOUSTON, May 4, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical stage biotechnology company, pioneering allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced that the U.S. Food and Drug Administration (FDA)
More news about: Cellenkos, Inc.
May 04, 2026, 16:05 ET BioMarin Reports First Quarter 2026 Financial and Operating Results
Conference ID: 3424435 About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
May 04, 2026, 11:40 ET SGS Acquires Keystone Bioanalytical, Strengthening End-to-End Drug Development Lifecycle Testing Capabilities for North American Pharma and Biotech Industries
GLP-compliant sites, positioning SGS as one of the most comprehensive, wholly owned analytical laboratory networks serving the pharmaceutical and biotechnology sectors worldwide.About SGSSGS is the world's leading Testing, Inspection and Certification company. We operate a network of
More news about: SGS
May 04, 2026, 11:11 ET Lilly declares second-quarter 2026 dividend
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 04, 2026, 11:00 ET FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity
partnership between FreeMind Group and Daewoong Pharmaceutical Co., Ltd., today announced its investment in General Proximity, a San Francisco-based biotechnology company pioneering the next generation of induced proximity medicines. General Proximity has built the first mechanism-agnostic proximity
More news about: General Proximity
May 04, 2026, 10:30 ET Biologics Safety Testing Market worth $9.66 billion by 2031 | MarketsandMarkets™
& Insights:By offering, in 2025, the product segment had the largest share of 41.9%.Pharmaceutical & biotechnology companies dominated the biologics safety testing products market in 2025 with a share of 56.0%.North America accounted for the largest
More news about: MarketsandMarkets
May 04, 2026, 09:00 ET AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR
best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
May 04, 2026, 07:00 ET Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference
company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.For more information on Bio-Techne and its brands, please visit
More news about: Bio-Techne Corporation
May 04, 2026, 07:00 ET Introducing Vylor: Corteva Spinoff to Propel Agriculture Further
With more than 4,000 germplasm patents and more than 2,000 biotechnology patents, Vylor's innovation engine will be anchored in the industry's most elite germplasm and transformative biotechnology, including a world-class pipeline that includes gamechangers like proprietary hybrid
More news about: Corteva, Inc.
May 04, 2026, 07:00 ET Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
May 04, 2026, 07:00 ET Ascidian Completes Dose Escalation Portion of Phase 1/2 STELLAR Trial of ACDN-01 for Stargardt Disease and Announces Expanded Clinical Study Plans
Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the completion of the adult dose escalation portion of the STELLAR Phase
More news about: Ascidian Therapeutics
May 04, 2026, 06:00 ET Syngene strengthens leadership team with two key appointments
(NSE: SYNGENE) (ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's team of over 8,300 employees including 5,700+ scientists, brings
More news about: Syngene International
May 04, 2026, 03:50 ET CS Analytical Announces Major Laboratory Expansion
growing our laboratory capacity to deliver innovative testing services with cutting-edge technology, we will not only better our Pharmaceutical, Biotechnology and Medical Device clients, but also continue to create high-quality jobs that reinforce our leadership position in the contract laboratory industry.
More news about: CS Analytical
May 02, 2026, 15:30 ET BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
Patient Information.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
May 01, 2026, 16:39 ET Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
of the stock option and RSU agreement covering the grant.About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
May 01, 2026, 16:05 ET INOVIO to Report First Quarter Financial Results on May 13, 2026
PLYMOUTH MEETING, Pa., May 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
May 01, 2026, 11:20 ET Rubin Rudman's John McGivney Named to Lawdragon's 2026 100 Managing Partners You Need to Know
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; hospitality companies; regulated industries, public entities and municipalities; insurance companies
More news about: Rubin Rudman
May 01, 2026, 09:15 ET Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that an interview of Chairman and CEO, Dr. Amit Kumar, will air on the
More news about: Anixa Biosciences, Inc.
May 01, 2026, 09:00 ET Diakonos Oncology Reports Positive Clinical Data from Phase 1 Pancreatic Cancer Study and Expanded Access Program in Glioblastoma at AACR and AAN 2026
Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced the presentation of new clinical
More news about: Diakonos Oncology